Zyversa Therapeutics Inc
NASDAQ:ZVSA

  • LAST PRICE
    0.3954
  • TODAY'S CHANGE (%)
    -0.0146 (-3.5610%)
  • Bid / Lots
    0.3970/ 2
  • Ask / Lots
    0.4000/ 8
  • Open / Previous Close
    0.4246 / 0.4100
  • Day Range
    0.3910
    0.4300
  • 52 Week Range
    0.3679
    25.0000
  • Volume
    901,502

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ZVSA
Zyversa Therapeutics Inc
8.0M
-0.2x
---
DFFN
Diffusion Pharmaceuticals Inc
7.9M
-0.5x
---
BZYR
Burzynski Research Institute Inc
7.9M
-9.1x
---
ADIL
Adial Pharmaceuticals Inc
7.8M
-0.5x
---
CWBR
CohBar Inc
7.8M
-0.7x
---
CYCC
Cyclacel Pharmaceuticals Inc
8.3M
-0.3x
---
As of 2023-05-27

Company Information

ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its development pipeline includes a renal drug candidate, namely VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for the treatment of a rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has the potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). The Company's development pipeline also includes an anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its renal product candidate, VAR 200, mediates the removal of excess intracellular lipids that contribute to kidney damage and lead to end-stage renal disease.

Contact Information

Headquarters
2200 N. Commerce Parkway, Suite 208WESTON, FL, United States 33326
Phone
754-231-1688
Fax
845-818-3588

Executives

Chairman of the Board, Chief Executive Officer
Stephen Glover
Chief Financial Officer
Peter Wolfe
Chief Scientific Officer
Nicholas LaBella
Chief Commercial Officer
Karen Cashmere
Director
Gregory Freitag

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$8.0M
Revenue (TTM)
$0.00
Shares Outstanding
20.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.60
Book Value
$10.85
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.